MindWalk Holdings Corp.
NASDAQ:HYFT · NASDAQ Global Market
+$0.01 today
Vol 0.27M · Avg 0.32M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:HYFT · Revenue to Net Income
Key Ratios
Analysis
$18.4M of revenue converted into -$12.2M of net income for the selected period. Gross margin is 59.0% and net margin is -74.1%, showing how much revenue survives after costs and taxes. EPS is $-0.29, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.5M +0.0% | $24.5M +18.6% | $20.7M +6.7% | $19.4M +8.1% | $17.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $11.0M -12.0% | $12.5M +36.9% | $9.1M +8.6% | $8.4M +31.5% | $6.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.5M +12.4% | $12.1M +4.2% | $11.6M +5.3% | $11.0M -4.8% | $11.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 55.3% +6.1pp | 49.2% -6.8pp | 56.0% -0.8pp | 56.7% -7.7pp | 64.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $4.9M +22.3% | $4.0M -71.3% | $14.1M +84.0% | $7.7M +288.2% | $2.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $19.0M -0.5% | $19.1M +0.8% | $19.0M +5.2% | $18.1M +36.1% | $13.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $25.7M -0.3% | $25.8M -30.6% | $37.2M +34.4% | $27.7M +76.0% | $15.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.1M -10.7% | $5.7M -14.2% | $6.7M +77.4% | $3.8M +1.5% | $3.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$28.9M -25.7% | -$22.9M -9.1% | -$21.0M -75.4% | -$12.0M -745.2% | -$1.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -117.7% -24.1pp | -93.6% +8.2pp | -101.8% -39.9pp | -61.9% -54.0pp | -7.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$12.2M +11.4% | -$13.8M +46.3% | -$25.6M -53.6% | -$16.7M -299.3% | -$4.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -49.7% +6.4pp | -56.1% +67.8pp | -123.9% -37.8pp | -86.1% -62.8pp | -23.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $23.0K -81.1% | $122.0K -56.3% | $279.0K +5.3% | $265.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $9.9K -47.8% | $19.0K -36.7% | $30.0K -64.7% | $85.0K -85.9% | $602.4K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$22.1M -47.7% | -$14.9M -597.9% | -$2.1M -359.5% | $825.0K +145.4% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$34.3M -19.4% | -$28.7M -3.4% | -$27.8M -75.1% | -$15.8M -164.4% | -$6.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -139.8% -22.7pp | -117.1% +17.2pp | -134.3% -52.5pp | -81.8% -48.4pp | -33.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$4.0M -55.8% | -$2.6M -117.1% | -$1.2M -238.4% | $861.0K -36.0% | $1.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$30.2M -15.8% | -$26.1M +1.7% | -$26.6M -59.0% | -$16.7M -127.6% | -$7.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -123.3% -16.8pp | -106.5% +22.0pp | -128.5% -42.2pp | -86.3% -45.3pp | -41.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +12.6% | -$1 +3.7% | -$1 -23.0% | -$1 -93.3% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +12.6% | -$1 +3.7% | -$1 -23.0% | -$1 -93.3% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $33.4M +30.2% | $25.6M +3.0% | $24.9M +26.5% | $19.7M +19.5% | $16.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $33.4M +30.2% | $25.6M +3.0% | $24.9M +26.5% | $19.7M +19.5% | $16.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

ALX Oncology Holdings Inc.
NASDAQ:ALXO
$191.08M

Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$145.71M
Repare Therapeutics Inc.
RPTX
$114.24M

Fortress Biotech, Inc.
NASDAQ:FBIO
$100.82M

CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$88.36M

BeyondSpring Inc.
NASDAQ:BYSI
$66.41M

Clene Inc.
NASDAQ:CLNN
$62.05M

Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$60.93M
aTyr Pharma, Inc.
ATYR
$44.97M
Quince Therapeutics, Inc.
QNCX
$5.07M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HYFT generate?
MindWalk Holdings Corp. (HYFT) reported $24.52M of revenue in fiscal 2025.
Is HYFT profitable?
MindWalk Holdings Corp. (HYFT) reported -$30,234,000.00 of net income, with a net margin of -123.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.